DSIP: A Sleep Peptide Nobody Can Fully Explain

The short version

DSIP stands for Delta Sleep-Inducing Peptide — a very small protein fragment first found in the blood of rabbits during an experiment that put them into deep sleep with electrical stimulation. The name promises more than the science can fully back up: more than forty years later, researchers still haven't identified a DSIP receptor, gene, or precursor, and a major 2006 review called the whole sleep-inducing story "a still unresolved riddle" ^[2].

That doesn't mean nothing is there — some modern animal work looks genuinely encouraging ^[1][3] — but it does mean DSIP's reputation as a reliable natural sleep aid runs well ahead of what has actually been proven. Community reports back this up in an interesting way: roughly half the people who try it say it does nothing at all. This page describes what has been studied, in which species, and how strong that evidence really is — never a dose, never a recommendation.

What it is

DSIP is a linear nonapeptide — a chain of just nine amino acids — with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (shorthand WAGGDASGE) and the molecular formula C35H48N10O15. It was first isolated by the researchers Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced sleep, which is where both its name and its early promise come from.

A naturally occurring phosphorylated variant, DSIP-P, is also described in the scientific literature and is reported in some laboratory assays to be more potent than the unmodified peptide. Its International Nonproprietary Name, Emideltide, exists on paper, but no Emideltide drug product has ever been approved or marketed by any regulator — DSIP remains a research chemical, not a medicine, anywhere in the world.

How it works

Here is the honest, slightly unusual answer: nobody knows, exactly. Unlike most modern drugs, which bind a specific, well-mapped receptor, DSIP has no identified receptor, gene, or precursor protein despite decades of searching. It is a bit like knowing a key opens some kind of lock somewhere in the house, without knowing which door.

A few pieces of the picture are better characterized. DSIP appears to cross into the brain via a saturable transporter at the blood-brain barrier — one that is competitively blocked by the amino acid L-tryptophan, suggesting it shares a transport route with tryptophan rather than having a dedicated door of its own. Some of its effects on growth hormone in animal studies run through a dopamine-related relay that is blocked by the drug pimozide, hinting at an indirect, several-steps-removed action rather than a direct "flip the sleep switch" mechanism. Older withdrawal-syndrome studies have also proposed a link to the body's own opioid signaling system, though this remains a hypothesis rather than an established pathway.

What the research shows

Modern animal work (2024). Researchers engineered a DSIP fusion peptide (DSIP-CBBBP) designed to cross the blood-brain barrier more efficiently than native DSIP, and tested it in mice made insomniac with the drug PCPA. The fusion peptide cut average daily wakefulness from roughly 720 minutes to about 500 minutes — a reduction of around 31% — while also restoring melatonin, serotonin and dopamine levels, producing anxiolytic and antidepressant-like behavioral effects, and increasing hippocampal neuron density. It outperformed unmodified DSIP on every measure ^[1].

The honest counterweight (2006 review). A review in the Journal of Neurochemistry examined decades of DSIP research and concluded the link between DSIP and sleep was never fully characterized: the sleep-promotion hypothesis is, in the authors' words, "extremely poorly documented and still weak," no DSIP gene, protein, or receptor has ever been isolated, and — pointedly — synthetic DSIP analogs, not native DSIP itself, produced the clearest sleep-promoting effects in the studies that did work ^[2].

Longevity and cancer signal in mice (2003). Monthly five-day courses of a DSIP-containing preparation called Deltaran (about 100 micrograms per kilogram) given to female SHR mice increased maximum lifespan by 24.1%, extended survival of the longest-lived 10% of animals by 17.1%, cut spontaneous tumor incidence by 2.6-fold, and reduced bone-marrow chromosome damage by 22.6% ^[3]. These are striking numbers from a single research lineage and have not been broadly independently replicated.

Human hormone studies (1989 and 1981). In men, an intravenous dose of DSIP (25 nanomoles per kilogram) significantly lowered a marker of the stress hormone ACTH for at least three hours, while cortisol itself was unaffected and simply followed its normal daily decline ^[4]. In an earlier, smaller trial, the same intravenous dose given to six middle-aged people with chronic insomnia improved several measures of disturbed sleep — longer duration, fewer interruptions, slightly more REM sleep, and no daytime grogginess — with the effect emerging in the second hour after the injection ^[5].

Reported effects, cautions & safety

People discussing DSIP in sleep-optimization and peptide research communities describe a genuinely mixed picture. These are anecdotal, not clinical evidence — forum and community reports, not measured trial outcomes — and none of it involves a recommended dose.

Reported benefits (anecdotal, not clinical evidence): the most common upside people describe is an easier transition into sleep — a quieter mind and fewer racing thoughts, arriving within minutes for some. Responders often say the sleep itself feels deeper and more restorative, with fewer nighttime wake-ups, and many contrast waking up feeling genuinely rested and clear-headed with the heavy grogginess they associate with melatonin or prescription sleep aids. A smaller group describe a calmer, lower-stress feeling that extends beyond sleep itself.

Mixed and inconsistent reports (anecdotal, not clinical evidence): vivid, more memorable dreams come up constantly, and most people find this pleasant, though a minority find the intensity disruptive. Some in fitness and recovery communities use it around hard training blocks hoping better sleep aids recovery, though there's no consensus it does anything beyond whatever sleep benefit a given person gets. The single most important honest signal, though, is non-response: a large share of people say DSIP did nothing for them at all, with one commonly repeated practitioner estimate putting the response rate at only about half of those who try it. People expecting a gentle nudge toward sleep tend to report better experiences than those expecting to be knocked out.

Reported downsides (anecdotal, not clinical evidence): headache is the single most commonly reported side effect, usually mild and transient, though one forum account described a headache that lingered for days. A notable minority describe unpredictable or delayed timing — including sedation arriving the following day during work hours rather than that night — and a smaller group report the opposite of the "no hangover" experience: a heavy, dragging morning, more likely at heavier use. Mild nausea, dizziness or lightheadedness are occasionally mentioned as well.

Cited cautions from the clinical literature:

• Sold only as an unregulated research chemical. DSIP is not an approved drug anywhere; even though "Emideltide" is its official name on paper, no Emideltide product has ever reached the market, so material bought online carries no pharmaceutical purity, dose-accuracy, or sterility standard ^[2].
• The mechanism is genuinely unknown, which makes interactions unpredictable. With no identified receptor, gene, or precursor after forty-plus years of study, there's no sound scientific basis for predicting how DSIP might interact with medications or supplements ^[2].
• Long-term human safety data are essentially absent. Human study of DSIP is limited to small pilot trials from the 1980s and short hormone experiments; its measured plasma half-life in animals is only minutes, and no large or long-duration human safety study exists ^[5].
• Chasing sleep with an unproven peptide can mask a real, treatable sleep disorder. Persistent trouble sleeping can signal conditions like sleep apnea or a thyroid problem, and DSIP has not been shown in modern controlled trials to treat any diagnosed sleep disorder ^[5].
• Combining DSIP with sedatives, sleep medications, or alcohol has never been formally tested, and the absence of reported problems in a handful of tiny 1980s studies is not evidence that stacking it with other sedating substances is safe.
• Effects in pregnancy and in people with pre-existing conditions are entirely unstudied, and since DSIP has been reported to touch stress-hormone and reproductive signaling in animals, the consequences for these groups simply cannot be predicted from the available data ^[2].
• Reported benefits are inconsistent and frequently absent, both in the formal literature and in community experience, so treating DSIP as a reliable sleep solution is not supported by the evidence ^[2].

Where it fits in calm, focus and sleep research

DSIP is the sleep-end anchor on this desk — a compound whose folklore reputation as a natural sleep switch outpaces what four decades of research have actually nailed down. Where Semax works through a comparatively well-mapped mechanism (raising brain growth factors like BDNF and NGF), DSIP's core honesty is that its mechanism is still, by researchers' own description, an unresolved riddle ^[2]. Reading the two together shows two very different starting points for evaluating a nootropic-adjacent peptide: one with real but incomplete mechanistic evidence, and one whose biggest, most reliable finding may be how often it does nothing at all. See the comparison page for the side-by-side.